Skip to main content

Locally Advanced Pancreatic TIGeR-PaC

Status: Open to Enrollment
Email Us To Enroll

Study Details

View study details on www.clinicaltrials.gov.

Locations

  • Sacramento

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC (TIGeR-PaC)

The study is a multi-center, un-blinded, randomized control study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.

Christopher J Laing, M.D.
Christopher J Laing, M.D.
Principal investigator
View Profile

Co-investigators

Aria Sasaki, M.D., Deepti Behl, M.D., Sivakumar Reddy, M.D., Vijay Suhag, M.D., Carlin R Hauck, M.D., Christopher U Jones, M.D., FACR, Charlotte D Kubicky, M.D., Jasdeepa Nagi, M.D., Hubert Y Pan, M.D., M.S., Anthony T Pu, M.D., Benjamin G Coombs, D.O., Henal H Patel, M.D.

Funder

RenovoRx

Email Us to Enroll

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?